Mini Review: Changes in the Incidence of and Progression to Proliferative and Sight-Threatening Diabetic Retinopathy Over the Last 30 Years

Ophthalmic Epidemiology

Volumn 24, Issue 2, 2017, Pages 73-80

  Liew, Gerald ^a   Wong, Vincent W ^b   Ho, I Van ^c,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Ingham Institute of Applied Medical Research   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d MACQUARIE UNIVERSITY   (Australia)

Author keywords

Diabetes; diabetic retinopathy; epidemiology; proliferative diabetic retinopathy; review

Indexed keywords

DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE SEVERITY; FOLLOW UP; HUMAN; INCIDENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROLIFERATIVE DIABETIC RETINOPATHY; REVIEW; SIGHT THREATENING DIABETIC RETINOPATHY; SYSTEMATIC REVIEW; TREND STUDY; COMPLICATION; DISEASE COURSE; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; TIME FACTOR;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE PROGRESSION; HUMANS; INCIDENCE; TIME FACTORS;

EID: 85010002198     PISSN: 09286586     EISSN: 17445086     Source Type: Journal    
DOI: 10.1080/09286586.2016.1259638     Document Type: Review

References (42)

1. Effect of ruboxistaurin in patients with diabetic macular edema:thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol 2007;125:318–324.
2. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy, ETDRS Report Number 12. Ophthalmology 1991;98:823–833.
3. Davis MD, Fisher MR, Gangnon RE, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss:Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 1998;39:233–252.
4. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol 1989;107:244–249.
5. Liew G, Michaelides M, Bunce C., A comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999–2000 with 2009–2010. BMJ Open 2014;4:e004015.
6. Klein R, Lee KE, Knudtson MD, et al. Changes in visual impairment prevalence by period of diagnosis of diabetes:the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology 2009;116:1937–1942.
7. Klein R, Klein BE., Is the prevalence of visual impairment rising or falling in the people with diabetes mellitus? It depends on who you study. JAMA Ophthalmol 2013;131:948–950.
8. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy:XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105:1801–1815.
9. Broe R, Rasmussen ML, Frydkjaer-Olsen U, et al. The 16-year incidence, progression and regression of diabetic retinopathy in a young population-based Danish cohort with type 1 diabetes mellitus:The Danish Cohort of Pediatric Diabetes 1987 (DCPD1987). Acta Diabetol 2014;51:413–420.
10. Kyto JP, Harjutsalo V, Forsblom C, et al. Decline in the cumulative incidence of severe diabetic retinopathy in patients with type 1 diabetes. Diabetes Care 2011;34:2005–2007.
11. Grauslund J, Green A, Sjolie AK., Prevalence and 25 year incidence of proliferative retinopathy among Danish type 1 diabetic patients. Diabetologia 2009;52:1829–1835.
12. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol 1989;107:244–249.
13. Klein R, Knudtson MD, Lee KE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy:XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008;115:1859–1868.
14. Younis N, Broadbent DM, Vora JP, et al. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study:a cohort study. Lancet 2003;361:195–200.
15. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [see comments]. Lancet 1998;352:837–853.
16. Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50:risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001;44:156–163.
17. Scanlon PH, Stratton IM, Histed M, et al. The influence of background diabetic retinopathy in the second eye on rates of progression of diabetic retinopathy between 2005 and 2010. Acta Ophthalmol 2013;91:e335–e339.
18. Jones CD, Greenwood RH, Misra A, et al. Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England. Diabetes Care 2012;35:592–596.
19. Muqit MM, Yang Y, Lipinski H, et al. Progression of pre-proliferative to proliferative diabetic retinopathy:a 3-year study in the Oxford population-based diabetic retinopathy screening programme. Diabet Med 2014;31:1018–1019.
20. Dutra MM, Mesquita E, Gardete-Correia L, et al. First Incidence and Progression Study for Diabetic Retinopathy in Portugal, the RETINODIAB Study:evaluation of the screening program for Lisbon Region. Ophthalmology 2015;122:2473–2481.
21. Looker HC, Nyangoma SO, Cromie DT, et al. Rates of referable eye disease in the Scottish National Diabetic Retinopathy Screening Programme. Br J Ophthalmol 2014;98:790–795.
22. Sjolie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2):a randomised placebo-controlled trial. Lancet 2008;372:1385–1393.
23. Keech A, Mitchell P, Summanen P, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study):a randomised controlled trial. Lancet 2007;370:1687–1697.
24. Wong TY, Mwamburi M, Klein R, et al. Rates of progression in diabetic retinopathy during different time periods:a systematic review and meta-analysis. Diabetes Care 2009;32:2307–2313.
25. English National Screening Committee. http://diabeticeye screening nhs uk/about [serial online] 2014.
26. American Academy of Ophthalmology and International Clinical Diabetic Retinopathy Disease Severity Scale. American Academy of Ophthalmologists [serial online] 2007.
27. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [see comments]. Lancet 1998;352:837–853.
28. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703–713.
29. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology 1995;102:647–661.
30. Mohamed Q, Gillies MC, Wong TY., Management of diabetic retinopathy:a systematic review. JAMA 2007;298:902–916.
31. Gaede P, Vedel P, Parving HH, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria:the Steno type 2 randomised study. Lancet 1999;353:617–622.
32. Younis N, Broadbent DM, Harding SP, et al. Incidence of sight-threatening retinopathy in Type 1 diabetes in a systematic screening programme. Diabet Med 2003;20:758–765.
33. Lee R, Wong TY, Sabanayagam C., Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond) 2015;2:17.
34. Lund SH, Aspelund T, Kirby P, et al. Individualised risk assessment for diabetic retinopathy and optimisation of screening intervals:a scientific approach to reducing healthcare costs. Br J Ophthalmol 2016 May;100(5):683–7.
35. World Health Organization. Prevention of blindness from diabetes mellitus. http://www who int/diabetes/publications/prevention_diabetes2006/en/[serial online] 2006.
36. Yeh RW, Czarny MJ, Normand SL, et al. Evaluating the generalizability of a large streamlined cardiovascular trial:comparing hospitals and patients in the dual antiplatelet therapy study versus the National Cardiovascular Data Registry. Circ Cardiovasc Qual Outcomes 2015;8:96–102.
37. Rothwell PM., External validity of randomised controlled trials:“to whom do the results of this trial apply?” Lancet 2005;365:82–93.
38. Xu J, Wei WB, Yuan MX, et al. Prevalence and risk factors for diabetic retinopathy:the Beijing Communities Diabetes Study 6. Retina 2012;32:322–329.
39. Saumya PS, Raman R, Ganesan S, et al. Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN–DREAMS III):study design and research methodology. BMC Ophthalmol 2011;11:7.
40. Chiang PP, Lamoureux EL, Cheung CY, et al. Racial differences in the prevalence of diabetes but not diabetic retinopathy in a multi-ethnic Asian population. Invest Ophthalmol Vis Sci 2011;52:7586–7592.
41. Virgili G, Menchini F, Murro V, et al. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. Cochrane Database Syst Rev 2011;CD008081.
42. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233–244.